We have acquired exclusive rights to several drugs against a number of human diseases. Our current portfolio of product candidates in pre-clinical development include two anti-cancer agents targeting four different tumors (Kevetrin and KM3174); one candidate targeting rheumatoid arthritis (KM277); a small molecule compound with an indication of osteo-arthritis/asthma (KM278); a small molecule compound with an indication of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson’s Disease (KM362) a small molecule compound for the treatment of Psoriasis (Prurisol-KM133) and a small molecule compound for the treatment of autism (KM-391).
|Prurisol||Psoriasis||Phase 2/3 505(b)(2)|
|KM 3174||Cancer||Early R&D|
|KM 362||MS/ALS/Park||Early R&D|
|KM 732||Hypertensive emergency||Early R&D|
In-vivo studies on over 1000 animal subjects have been conducted to check for efficacy of the compound in rheumatoid arthritis. Related in vitro assays including ex-vivo studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the disease
This compound showed efficacy in both Osteo-arthritis animal models and Asthma models in animals. We tested the compounds against standard treatment against both asthma and Osteo-arthritis and based on the data. These studies have resulted in the Company’s management to believe that the compound has developmental potential for the treatment of the diseases
Demyelination is characteristic in most neurological diseases, where there is no treatment at all, as in case of Lou Gehrig Disease, Parkinson’s Disease and Multiple Sclerosis, etc. Initial study results are conclusive of the compounds ability to target all of these neurological diseases. These early studies indicate this compound aids in myelination along with strengthening the functions of the nerves, spinal cord and the brain tissue.
This is a very early stage developmental compound in the treatment of cancer. After additional in vitro and in vivo studies the Company will determine whether to advance this compound for further development.
A small molecule which shows properties in the reduction of high blood pressure.
Preliminary testing in rats revealed that test animals showed a significant decrease in both systolic and diastolic blood pressure compared to controls, with no apparent toxicity. Clinical observation of the animals indicated that blood pressure was reduced within a few minutes of the administration of the compound. The Company plans to conduct proof of concept studies in large animals to evaluate the compound’s potential for development to treat hypertensive emergency. Hypertensive emergency is a potentially life-threatening condition characterized by uncontrolled blood pressure leading to damage to other organs.
Hypertensive emergency is a serious condition affecting over 500,000 Americans per year, thus warranting our early investigational efforts into KM732.